SIGA’s TPOXX RFP Timelines and Revenue Signals Clash in 2025 Q4 Earnings Call

Date of Call: Mar 10, 2026

Financials Results

• Revenue: $88M product revenue for 2025, including $53M oral TPOXX, $26M IV TPOXX, and $6M international oral sales.
• EPS: $0.32 per diluted share for 2025.
• Operating Margin: $24M pretax operating income for 2025.

Business Commentary:

Smallpox Preparedness and Government Partnerships:

• SIGA Technologies achieved $88 million in product revenues in 2025, driven by sales of $53 million in oral TPOXX and $26 million in IV TPOXX to the U.S. Strategic National Stockpile, as well as $6 million from international sales.
• The focus on smallpox preparedness and strong government partnerships, particularly with the U.S. government, underpin this revenue, with ongoing discussions for future contracts.

Financial Performance and Stability:

• The company reported a pretax operating income of $24 million and net income of $23 million for 2025, with a strong cash balance of $155 million and no debt.
• This financial stability is attributed to consistent product deliveries and additional funding secured from the U.S. government for development and manufacturing.

International Engagement and Orders:

• SIGA received a $13 million order for TPOXX from a country in the Asia Pacific region, highlighting increasing international interest in smallpox preparedness.
• This reflects a broader trend of countries reassessing their health security strategies, leading to potential stockpiling of TPOXX.

Regulatory and Developmental Progress:

• The European Medicines Agency's Committee for Medicinal Products for Human Use is expected to meet in March to review the marketing authorization for Tecovirimat-SIGA, with a focus on maintaining its smallpox indications.
• SIGA is also advancing its post-exposure prophylaxis program, targeting an FDA submission within the next 12 months, supported by collaborations with the CDC and BARDA.

Sentiment Analysis:

Overall Tone: Positive

• Management stated: 'SIGA entered 2026 from a position of strength, defined by strategic focus, financial discipline and durable government partnerships.' They highlighted solid financial results, active U.S. government engagement, a new international order, and ongoing pipeline progress.

Q&A:

• Question from Jyoti Prakash (Edison Investment Research Limited): Starting off with the U.S. RFP. BARDA recently issued a sources sought notice for smallpox vaccines, which strongly suggest preparedness remains a priority for the government. Now based on your ongoing discussions with the authorities, do you have any updated visibility on the timing of the next U.S. government RFP for TPOXX?
  Response: Management confirmed smallpox preparedness remains a government focus but provided no specific timing for the next RFP, emphasizing productive discussions and TPOXX's critical role.

• Question from Jyoti Prakash (Edison Investment Research Limited): And my next question relates to the capital allocation. And SIGA's ended the year with a strong cash position. You mentioned $155 million in cash and no debt on the books. So how should we think about your capital allocation priorities looking ahead? Can we expect continued special dividends as we've seen 2 to 3 years? Or could you take a different approach looking forward?
  Response: CFO stated capital management aims to support long-term value creation; timing for special cash dividend decision is typically March-May, with no details yet.

• Question from Jyoti Prakash (Edison Investment Research Limited): Are you also open to acquisitions or in-licensing opportunities to broaden the pipeline?
  Response: CEO affirmed the company is capable and open to pursuing strategic M&A or investments that align with creating shareholder value and advancing health security.

• Question from Jyoti Prakash (Edison Investment Research Limited): And just if I can follow up on the question. Are we right in assuming that this relates to the same customer that placed the $11 million order in late 2024. And following from that, could you provide a bit more color on the contract duration, the potential order frequency and then the size of the contract? And finally, can we expect additional international orders through the year?
  Response: CFO clarified the $13M Asia Pacific order is from a repeat but different customer, involves a multiyear contract with flexible ordering, and additional international sales may occur but processes are complex and timing uncertain.

Contradiction Point 1

Impact of Government Shutdown on RFP Process

Contradiction on whether government shutdowns caused material delays or were merely a non-issue.

Jyoti Prakash (Edison Investment Research Limited) - Jyoti Prakash (Edison Investment Research Limited)

20251107-2025 Q3: The government shutdown has not materially impacted operational activities or existing contracts... However, there could be delays in the CDC completing analysis for the PEP program, potentially slipping from completion later this year. - Diem Nguyen(CEO)

Based on ongoing discussions with authorities, do you have updated visibility on the timing of the next U.S. government RFP for TPOXX following BARDA's recent sources sought notice on smallpox vaccines? - Jyoti Prakash (Edison Group)

2025Q4: The sources sought notice and U.S. government actions over the past 12 months indicate that smallpox preparedness remains an important focus. ... and TPOXX remains an important component of the U.S. preparedness strategy. - Diem Nguyen(CEO)

Contradiction Point 2

Nature of Product Revenue

Contradiction on whether small product revenue is indicative of a trend or a one-off accounting item.

Jyoti Prakash (Edison Investment Research Limited) - Jyoti Prakash (Edison Investment Research Limited)

2025Q4: The $13 million order from the Asia Pacific region reflects progress in strengthening relationships with global government partners focused on enhancing smallpox preparedness. - Daniel Luckshire(CFO)

Can you provide more details on the contract duration, order frequency, contract size, and potential international orders expected this year? - Jyoti Prakash (Edison Group)

20251107-2025 Q3: The small product revenue in Q3 was due to specific accounting for certain reimbursement activities... It does not reflect a trend. - Daniel Luckshire(CFO)

Contradiction Point 3

U.S. Government RFP for TPOXX - Timeline Clarity

Inconsistent statements regarding the availability of specific timing details for the RFP process.

Jyoti Prakash (Edison Investment Research Limited) - Jyoti Prakash (Edison Investment Research Limited)

2025Q4: Regarding timing, no additional details can be shared today. - Diem Nguyen(CEO)

Do you have updated visibility on the timing of the next U.S. government RFP for TPOXX? - Jyoti Prakash (Edison Investment Research Limited)

2025Q2: SIGA is prepared for efficient negotiations, referencing the 2018 process which took 6 months from RFP to contract finalization, though the timeline could vary. - Daniel J. Luckshire(CFO)

Contradiction Point 4

International Order Timing and Predictability

Contradictory characterizations of the predictability and lumpiness of international order timing.

Jyoti Prakash (Edison Investment Research Limited) - Jyoti Prakash (Edison Investment Research Limited)

2025Q4: SIGA remains actively engaged with a range of international customers. Updates will be provided when announcements are ready. - Daniel Luckshire(CFO)

Could you provide details on the contract duration, order frequency, and size of the $13 million TPOXX order, and whether additional international orders are expected in 2026? - Jyoti Prakash (Edison Investment Research Limited)

2025Q2: International orders are expected to remain 'lumpy' in timing. - Daniel J. Luckshire(CFO)

Contradiction Point 5

U.S. RFP Timing and Future Government Procurement Plans

Contradiction on the level of detail regarding the timing of the next U.S. government RFP for TPOXX.

Jyoti Prakash (Edison Investment Research Limited) - Jyoti Prakash (Edison Investment Research Limited)

2025Q4: Regarding timing, no additional details can be shared today. - Diem Nguyen(CEO)

Do you have updated visibility on the timing of the next U.S. government RFP for TPOXX? - Jyoti Prakash (Edison Group)

2025Q1: SIGA regularly engages with government agencies and will continue to do so when the RFP is issued. - Diem Nguyen(CEO)